The AKR inhibitor, ponalrestat (statil) is reported to inhibit cancer cachexia by suppressing IL-1 expression [164] Ponalrestat was found to suppress the proliferation of breast and lung cancer cells by downregulating the expression of AKR1B10 [165]. This evidence concerns the gene AKR1B10 and lung cancer.